Related Experiment Video
Updated: Jan 17, 2026
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
The future of type 1 diabetes therapy
Anette-Gabriele Ziegler1, Eda Cengiz2, Thomas W H Kay3
1Institute of Diabetes Research, Helmholtz Munich, German Research Center for Environmental Health, Munich, Germany; School of Medicine and Health, Forschergruppe Diabetes at Klinikum rechts der Isar, Technical University of Munich and TUM University Hospital, Munich, Germany.
New treatments for type 1 diabetes are emerging, including immunotherapy to delay onset and advanced therapies for beta-cell preservation and replacement. Innovations in glucose monitoring and insulin delivery aim to improve long-term management and quality of life.
Area of Science:
- Immunology
- Endocrinology
- Regenerative Medicine
Background:
- Type 1 diabetes treatment is advancing rapidly.
- Early diagnosis through screening and disease-modifying treatments are becoming more accessible.
- Beta-cell replacement therapies are evolving beyond traditional transplantation.
Purpose of the Study:
- To review recent breakthroughs in type 1 diabetes management.
- To highlight novel immunotherapies, beta-cell replacement strategies, and glucose regulation technologies.
- To discuss the potential impact of these innovations on patient outcomes and quality of life.
Main Methods:
- Review of emerging immunotherapies, such as teplizumab.
- Exploration of stem cell-derived beta-cell therapies and bioengineering approaches.
- Assessment of advancements in automated insulin delivery and new-generation insulins.
Main Results:
- Teplizumab, an immunotherapy, is approved to delay clinical type 1 diabetes.
- Stem cell-derived beta cells and bioengineering offer new avenues for beta-cell replacement, potentially reducing immunosuppression needs.
- Automated insulin delivery systems and novel insulins enhance glucose control and minimize blood sugar fluctuations.
Conclusions:
- Transformative treatments offer renewed hope for type 1 diabetes management.
- Innovations in immunotherapy, beta-cell replacement, and glucose regulation promise improved long-term outcomes.
- Widespread implementation of these advanced therapies remains a significant challenge.
More Related Videos
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:22Diabetes Mellitus: Type 2 and Gestational
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...